Similar Papers

Paper Title
Journal
Date
Author
Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?
Jordi Remon ... Benjamin Besse
Journal of Thoracic Oncology | VOL. 14
Jordi Remon, et. al.Jordi Remon ... Benjamin Besse
23 Apr 2019
How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy
A Fundytus ... I.F Tannock
Annals of Oncology | VOL. 32
A Fundytus, et. al.A Fundytus ... I.F Tannock
08 Apr 2021
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
J Remon ... S Peters
Annals of Oncology | VOL. 32
J Remon, et. al.J Remon ... S Peters
01 Sep 2021
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.
Eleonora De Martin ... Catherine Guettier
JHEP Reports | VOL. 2
Eleonora De Martin, et. al.Eleonora De Martin ... Catherine Guettier
11 Aug 2020
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
A Perspective on the MARS2 Trial
Eric Lim ... Harvey Pass
Journal of Thoracic Oncology | VOL. -
Eric Lim, et. al.Eric Lim ... Harvey Pass
01 Jan 2025
Meeting Announcements
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
Editorial Board
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03
Afshin Dowlati ... Saiama N Waqar
Journal of Thoracic Oncology | VOL. -
Afshin Dowlati, et. al.Afshin Dowlati ... Saiama N Waqar
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.